Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 25Terminated 16Withdrawn 10Unknown 3Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 1Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × epacadostat × Clear all
NCT03414229 2026-04-23

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled 11 charts
Sarcoma

Sarcoma

NCT04463771 2025-12-10

POD1UM-204

Incyte Corporation

Phase 2 Active not recruiting
206 enrolled
Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡